Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2022-04-29 Interim / Quarterly Rep…
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Delårsrapport 1 januari – 31 mars 2022' (Interim Report for Jan 1 – Mar 31, 2022). It contains comprehensive financial data, including income statements, balance sheet information, management commentary, and operational updates for the first quarter. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2022
2022-04-29 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Report 1 January – 31 March 2022' and contains comprehensive financial statements, management commentary, and operational updates for the first quarter of 2022. It provides detailed financial data (net sales, loss for the period, earnings per share) and business analysis, fitting the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-04-29 English
Episurf Medicals Episealer® Patellofemoral System nu under ”substantive review” hos amerikanska FDA
Regulatory Filings Classification · 1% confidence The document is a short announcement from Episurf Medical regarding the status of its 510(k) application for the Episealer® Patellofemoral System with the US FDA, stating it has moved to 'substantive review'. It includes a quote from the CEO and standard company boilerplate. The text explicitly mentions that this information is being made public according to the EU Market Abuse Regulation ('EU:s marknadsmissbruksförordning'). This type of announcement, which is a specific regulatory update concerning a product approval process rather than a comprehensive financial report (like 10-K or IR) or a management change (MANG), fits best under the general 'Regulatory Filings' category (RNS) as it is a mandatory disclosure of a material event. It is too short and not a financial report itself, ruling out AR, 10-K, IR, ER, etc. It is not about dividends (DIV), director dealings (DIRS), or capital structure (CAP). Therefore, RNS is the most appropriate fallback for a material regulatory update that doesn't fit a more specific non-financial category.
2022-04-24 Swedish
Episurf Medical’s Episealer® Patellofemoral System under substantive review at the US FDA
Legal Proceedings Report Classification · 1% confidence The document is a short announcement from Episurf Medical regarding the progress of its 510(k) application for the Episealer® Patellofemoral System with the US FDA, stating it has entered the 'substantive review phase'. This is a specific update on a regulatory process, not a full financial report (like 10-K or IR) or a general regulatory filing (RNS). It is an announcement concerning a legal/regulatory matter involving the company and a government body (FDA). Given the options, this best fits under 'Legal Proceedings Report' (LTR) as it relates to regulatory clearance/action, or potentially 'Regulatory Filings' (RNS) as a general update. However, since it specifically details the status of a regulatory submission/review, and there isn't a dedicated 'Regulatory Submission Status' code, LTR (Legal Proceedings Report) is often used broadly for significant regulatory interactions, or RNS as the fallback. Given the context of FDA review, which is a critical regulatory step, and the short nature of the text (Menu vs Meal rule suggests RPA/RNS if it were just announcing a report), this is a direct update on a regulatory/legal hurdle. Since LTR is defined as 'Updates on significant lawsuits, regulatory actions, or legal matters', this regulatory update fits best here, although RNS is a strong secondary candidate if LTR is interpreted strictly as litigation. I will classify it as LTR due to the specific mention of the FDA review process.
2022-04-24 English
Nytt patentbeviljande i Hongkong för Episurf Medical
Report Publication Announcement Classification · 1% confidence The document is a short announcement in Swedish regarding a new patent granted in Hong Kong for Episurf Medical concerning a surgical instrument design. It includes a quote from the COO and contact information. The final paragraph states that the information is being made public according to the EU Market Abuse Regulation (MAR) and specifies the time of release (kl. 15:45 den 20 april 2022). This structure—a brief update on a specific corporate event (patent grant) released under MAR obligations—does not fit the specific categories like 10-K, ER, or IR. It is not a Director's Dealing (DIRS), a Dividend (DIV), or a major financing event (CAP). Since it is a specific regulatory disclosure that doesn't fit the primary financial report types, the most appropriate general category for miscellaneous regulatory announcements that are not explicitly defined elsewhere is 'Regulatory Filings' (RNS). Given the short length and nature as a specific corporate update, RNS is the best fit.
2022-04-20 Swedish
New patent approval in Hong Kong for Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces the granting of a new patent by the Intellectual Property Department (IPD) of Hong Kong for Episurf Medical concerning a surgical instrument design. This is a specific announcement related to intellectual property rights and innovation, not a standard financial filing like 10-K, ER, or IR. Among the provided categories, 'IP' (Intellectual Property) is the most fitting classification for a patent approval announcement. The document is short and serves as a direct announcement, making IP the correct choice over a general regulatory filing (RNS).
2022-04-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.